首页> 外文会议>Conference on Micro- and Nanotechnology Sensors, Systems, and Applications >IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer
【24h】

IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer

机译:IGF-1受体靶向纳米颗粒用于图像诱导治疗富含基质和耐药的人类癌症

获取原文

摘要

Low drug delivery efficiency and drug resistance from highly heterogeneous cancer cells and tumor microenvironment represent major challenges in clinical oncology. Growth factor receptor, IGF-1R, is overexpressed in both human tumor cells and tumor associated stromal cells. The level of IGF-1R expression is further up-regulated in drug resistant tumor cells. We have developed IGF-1R targeted magnetic iron oxide nanoparticles (IONPs) carrying multiple anticancer drugs into human tumors. This IGF-1R targeted theranostic nanoparticle delivery system has an iron core for non-invasive MR imaging, amphiphilic polymer coating to ensure the biocompatibility as well as for drug loading and conjugation of recombinant human IGF-1 as targeting molecules. Chemotherapy drugs, Doxorubicin (Dox), was encapsulated into the polymer coating and/or conjugated to the IONP surface by coupling with the carboxyl groups. The ability of IGF1R targeted theranostic nanoparticles to penetrate tumor stromal barrier and enhance tumor cell killing has been demonstrated in human pancreatic cancer patient tissue derived xenograft (PDX) models. Repeated systemic administrations of those IGF-1R targeted theranostic IONP carrying Dox led to breaking the tumor stromal barrier and improved therapeutic effect. Near infrared (NIR) optical and MR imaging enabled noninvasive monitoring of nanoparticle-drug delivery and therapeutic responses. Our results demonstrated that IGF-1R targeted nanoparticles carrying multiple drugs are promising combination therapy approaches for image-guided therapy of stroma-rich and drug resistant human cancer, such as pancreatic cancer.
机译:高度异质性癌细胞和肿瘤微环境的低药物传递效率和耐药性是临床肿瘤学的主要挑战。生长因子受体IGF-1R在人肿瘤细胞和肿瘤相关基质细胞中均过表达。 IGF-1R表达水平在耐药肿瘤细胞中进一步上调。我们已经开发了将IGF-1R靶向磁性氧化铁纳米颗粒(IONP)携带多种抗癌药物进入人类肿瘤的方法。该IGF-1R靶向治疗性纳米粒子递送系统具有铁芯,可用于非侵入性MR成像,两亲性聚合物涂层,以确保生物相容性以及重组人IGF-1作为靶向分子的载药和缀合。化学疗法药物阿霉素(Dox)被封装到聚合物涂层中和/或通过与羧基偶联而与IONP表面结合。在人胰腺癌患者组织衍生的异种移植(PDX)模型中已证明了IGF1R靶向治疗性纳米颗粒穿透肿瘤基质屏障并增强肿瘤细胞杀伤能力。对那些携带Dox的靶向治疗性IONP的IGF-1R的重复全身给药导致打破了肿瘤基质屏障并改善了治疗效果。近红外(NIR)光学和MR成像可对纳米颗粒药物的输送和治疗反应进行无创监测。我们的结果表明,携带多种药物的IGF-1R靶向纳米颗粒是有前途的联合治疗方法,可用于图像指导的富含基质和耐药性人类癌症(例如胰腺癌)的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号